Organization (Other)
Oswaldo Cruz Foundation
ClinicalTrials.gov lists Oswaldo Cruz Foundation as lead sponsor of 42 trials. It has 6 active development programs and 15 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 3 registered with a 2026 start date. The dashed outline is the pace from the 3 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo FIOCRUZ, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Oswaldo Cruz Foundation: 42 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (75)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| HIV Infections | 12 |
| COVID-19 | 7 |
| Malaria | 7 |
| Tuberculosis | 6 |
| Acquired Immunodeficiency Syndrome | 5 |
Showing 5 of 75 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 5 |
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 9 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 7 |
| 2017 | 8 |
Showing 10 of 20 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (6)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| BCG (Bacillus Calmette-Guérin) vaccine | COVID-19 | Phase 3 | 1 |
| Oral Pre-Exposure Prophylaxis (PrEP) (Tenofovir Disoproxil Fumarate/Emtricitabine) | HIV Infections | Not reported | 1 |
| Doxycycline | Chlamydia Infections | Not reported | 1 |
| Doxycycline | Gonorrhea | Not reported | 1 |
| Doxycycline | Syphilis | Not reported | 1 |
Showing 5 of 6 active programs.
Approved assets (15)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| emtricitabine / tenofovir 200/300 mg | 2 |
| Praziquantel 40 mg/kg | 1 |
| Non- specialist - Epclusa 400Mg-100Mg Tablet | 1 |
| Specialist - Epclusa 400Mg-100Mg Tablet | 1 |
| Yellow Fever Vaccination | 1 |
Showing 5 of 15 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 2 of 4 on time (n=4) |
Journals published in (182)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The American journal of tropical medicine and hygiene | 12 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 11 |
| Lancet (London, England) | 10 |
| Vaccine | 10 |
| The New England journal of medicine | 9 |
Showing 5 of 182 journals.
Financing and grant events (14)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-01-13 | NIH grant | 130,212 | Reporter |
| 2024-11-22 | NIH grant | 869,573 | Reporter |
| 2024-11-19 | NIH grant | 381,930 | Reporter |
| 2024-03-21 | NIH grant | 115,880 | Reporter |
| 2023-10-27 | NIH grant | 1,303,154 | Reporter |
Showing 5 of 14 events.
Organization relationships (43)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Rio de Janeiro State Research Supporting Foundation (FAPERJ) | Co sponsors trial with | 5 |
| The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Co sponsors trial with | 4 |
| Hospital Universitário Professor Edgard Santos | Co sponsors trial with | 3 |
| Access to Advanced Health Institute | Co sponsors trial with | 2 |
| Centre Hospitalier de Cayenne | Co sponsors trial with | 2 |
Showing 5 of 43 relationships.
Latest dated events (100)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-03 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 100 events.
Biomarker capability evidence (142)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGA | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| EPO | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 142 evidence rows.
Biomarkers this organization publishes on (127)
Shown in this order: most publications first.
Showing 5 of 127 biomarkers.
On Scientist.com
Oswaldo Cruz Foundation is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Fundacao OsWaldo Cruz (FIOCRUZ) on Scientist.com
For prices, more details, or to contact Fundacao OsWaldo Cruz (FIOCRUZ), visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.